Lung Cancer

LiveLung announced the launch of its new Chaplain Program.

It is very important to let the world know that no matter how healthy you think you are, if you have lungs, you can potentially develop lung cancer.

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.

Nancee Pronsati discusses a new patient-authored guide for managing ALK-directed treatment side effects in lung cancer and improving quality of life.

The first day of fall comes on September 22, and every year it feels like a reminder to pause.

Early trial results report progression-free survival and response rates for ateganosine, spevatamig, Annamycin and pumitamig; studies are currently enrolling.

Lutathera demonstrated antitumor activity in patients with metastatic bronchopulmonary neuroendocrine tumors.

For patients with MET exon 14-altered NSCLC, Tepmetko was associated with frequent side effects, although the safety profile is considered manageable.

Receiving a “Stand Up to Cancer Day” email gave me the strength to support a friend through her darkest cancer days.

When I think about standing up to cancer, I cannot separate the words from my own story.

For patients with advanced non-small cell lung cancer who progressed on two or more prior regimens, THIO with Libtayo elicited positive responses.

Perioperative immunotherapy for the treatment of non-small cell lung cancer is starting to exhibit survival benefits among patients, research has shown.

Over the past 20 years, there have been dramatic advances in treatment options for people diagnosed with non-small cell lung cancer

LiveLung invites the Pittsburgh community to its monthly educational meeting.

CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.

Patients with advanced, pretreated ROS1-positive NSCLC treated with zidesamtinib saw an objective response rate of 44%.

For some with previously untreated locally advanced or metastatic non-small cell lung cancer Rybrevant plus Lazcluze improved overall survival.

CURE spoke with Dr. Alexander Spira to learn what patients need to know about the KRAS G12C mutation and its treatment strategies.

In patients with EGFR-mutated NSCLC ivonescimab plus chemotherapy was associated with significant progression-free survival.

Dr. Eric Singhi sat down with CURE to break down the findings from the phase 3 FLAURA2 study, presented at the 2025 IASLC World Conference on Lung Cancer.

Dr. Myung-Ju Ahn shared notable data on ifinatamab deruxtecan for patients with previously treated extensive-stage small cell lung cancer.

People with EGFR+ NSCLC whose disease spread outside the brain after treatment with Tagrisso lived longer when they kept taking Tagrisso along with chemo.

A combination of Iza-bren and Tagrisso showed beneficial results as an initial treatment for advanced/metastatic EGFR-mutated non–small cell lung cancer.

Never-smoker Leah Phillips, co-founder of the Young Lung Cancer Initiative, raises awareness that anyone with lungs can develop lung cancer.

The FDA granted Breakthrough Therapy designation to olomorasib plus Keytruda for unresectable advanced or metastatic NSCLC with a KRAS G12C mutation.